Primary Site >> Pancreatic Cancer
Gene >> CHEK2
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Possible causes of chromosome instability: comparison of chromosomal abnormalities in cancer cell lines with mutations in BRCA1, BRCA2, CHK2 and BUB1. PMID: 15162061 Ref: No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer. PMID: 15217503 Ref: Cellular response and molecular mechanism of antitumor activity by leinamycin in MiaPaCa human pancreatic cancer cells. PMID: 15269600 |
Ref: Low frequency of CHEK2 mutations in familial pancreatic cancer. PMID: 16858628 Ref: Benzyl isothiocyanate-induced DNA damage causes G2/M cell cycle arrest and apoptosis in human pancreatic cancer cells. PMID: 17056792 |
Ref: Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer. PMID: 18381943 Ref: Is there any relationship between BRCA1 gene mutation and pancreatic cancer development? PMID: 19140568 |
Ref: Compound MMH01 possesses toxicity against human leukemia and pancreatic cancer cells. PMID: 19344682 Ref: Benzyl isothiocyanate sensitizes human pancreatic cancer cells to radiation therapy. PMID: 19482673 Ref: Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. PMID: 19519883 |
Ref: Clinical and genetic analysis of 18 pancreatic carcinoma/melanoma-prone families. PMID: 20041885 Ref: CHEK2 gene alterations in the forkhead-associated domain, 1100delC and del5395 do not modify the risk of sporadic pancreatic cancer. PMID: 20643596 |
Ref: Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation. PMID: 20013349 Ref: German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. PMID: 21207249 Ref: RNA binding protein CUGBP2/CELF2 mediates curcumin-induced mitotic catastrophe of pancreatic cancer cells. PMID: 21347286 |
Ref: Hsp90 stabilizes Cdc25A and counteracts heat shock-mediated Cdc25A degradation and cell-cycle attenuation in pancreatic carcinoma cells. PMID: 22843495 |
Ref: Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine. PMID: 23855452 Ref: Digalloylresveratrol, a novel resveratrol analog inhibits the growth of human pancreatic cancer cells. PMID: 23943154 |
Ref: Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer. PMID: 24276239 Ref: Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. PMID: 24353313 Ref: Coupling G2/M arrest to the Wnt/beta-catenin pathway restrains pancreatic adenocarcinoma. PMID: 24402132 Ref: Methylseleninic acid suppresses pancreatic cancer growth involving multiple pathways. PMID: 24447148 Ref: Epicatechin stimulates mitochondrial activity and selectively sensitizes cancer cells to radiation. PMID: 24516636 Ref: Elevated DNA damage response in pancreatic cancer. PMID: 25002126 Ref: SKLB316, a novel small-molecule inhibitor of cell-cycle progression, induces G2/M phase arrest and apoptosis in vitro and inhibits tumor growth in vivo. PMID: 25301449 |
Ref: Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients. PMID: 26483394 Ref: Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. PMID: 26641009 Ref: Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds. PMID: 26727920 Ref: Phosphoproteome Analysis of Invasion and Metastasis-Related Factors in Pancreatic Cancer Cells. PMID: 27014871 Ref: Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer? PMID: 27038244 Ref: Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. PMID: 27621574 |
Ref: The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome. PMID: 27488870 |
Ref: Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. PMID: 28726808 Ref: Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines. PMID: 29667044 Ref: Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. PMID: 29731985 Ref: Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. PMID: 29961768 Ref: Germline Variants and Risk for Pancreatic Cancer: A Systematic Review and Emerging Concepts. PMID: 30113427 |